Molecular Imaging

Everyone deserves a unique answer

Molecular imaging is one of the most advanced and exciting fields in medical diagnostic. As of April 2012, IBA created a strategic alliance with SK Capital Partners to create IBA Molecular a jointly-owned company derived from IBA’s molecular imaging division. SK Capital Partners owns 60% of the company while IBA has a 40% stake. IBA’s molecular imaging division is a world leader in the Nuclear Medicine market with its global network:  57 sites in Europe, the U.S., and Asia, and a significant manufacturing facility in Saclay, France.

Thanks to its manufacturing capabilities, the new products pipeline and its geographic coverage, the company is enhancing its business to become the best-in-class within the industry.  The new tracers will help to identify kidney cancer and Alzheimer’s disease earlier than ever previously imagined. These unprecedented medical breakthroughs have the potential to save countless lives and give hope to patients and their families .The premium position of IBA in the field of molecular imaging will lead the sector towards improvements in healthcare through the broader application of molecular imaging.